Ali A Asadi-Pooya1,2, Amir Tajbakhsh3, Amir Savardashtaki3,4. 1. Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. aliasadipooya@yahoo.com. 2. Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. aliasadipooya@yahoo.com. 3. Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
OBJECTIVE: About 30% of patients with epilepsy have drug-resistant seizures. The aim of the current endeavor was to systematically review the existing evidence on the potential applications of microRNAs as biomarkers in people with difficult to treat temporal lobe epilepsy (TLE). METHODS: MEDLINE (accessed from PubMed) and Scopus from inception to March 18, 2020 were systematically searched for related published articles. In both electronic databases, the following search strategy was implemented, and these keywords (in the title/abstract) were used: "microRNA" AND "temporal lobe epilepsy." Articles written in English that were human studies in people with epilepsy were all included in this search. RESULTS: We could identify 16 articles about different aspects of microRNAs in the serum of patients with TLE. However, only three studies robustly investigated microRNAs as potential biomarkers in the diagnosis of drug-resistant TLE (microRNA-155 (upregulated), microRNA-129-2-3p (upregulated), microRNA-153 (downregulated)). One small study provided class II, and two small studies provided class III evidence. CONCLUSION: While this systematic review identified three studies that provided some evidence on the potential applications of circulating serum microRNAs as biomarkers in people with drug-resistant TLE, the evidence is not robust yet. While these findings provide a new horizon, substantial challenges remain before the roles of microRNAs as biomarkers in the diagnosis of drug-resistant TLE can be translated into clinical practice.
OBJECTIVE: About 30% of patients with epilepsy have drug-resistant seizures. The aim of the current endeavor was to systematically review the existing evidence on the potential applications of microRNAs as biomarkers in people with difficult to treat temporal lobe epilepsy (TLE). METHODS: MEDLINE (accessed from PubMed) and Scopus from inception to March 18, 2020 were systematically searched for related published articles. In both electronic databases, the following search strategy was implemented, and these keywords (in the title/abstract) were used: "microRNA" AND "temporal lobe epilepsy." Articles written in English that were human studies in people with epilepsy were all included in this search. RESULTS: We could identify 16 articles about different aspects of microRNAs in the serum of patients with TLE. However, only three studies robustly investigated microRNAs as potential biomarkers in the diagnosis of drug-resistant TLE (microRNA-155 (upregulated), microRNA-129-2-3p (upregulated), microRNA-153 (downregulated)). One small study provided class II, and two small studies provided class III evidence. CONCLUSION: While this systematic review identified three studies that provided some evidence on the potential applications of circulating serum microRNAs as biomarkers in people with drug-resistant TLE, the evidence is not robust yet. While these findings provide a new horizon, substantial challenges remain before the roles of microRNAs as biomarkers in the diagnosis of drug-resistant TLE can be translated into clinical practice.
Authors: Jerome Engel; Michael P McDermott; Samuel Wiebe; John T Langfitt; John M Stern; Sandra Dewar; Michael R Sperling; Irenita Gardiner; Giuseppe Erba; Itzhak Fried; Margaret Jacobs; Harry V Vinters; Scott Mintzer; Karl Kieburtz Journal: JAMA Date: 2012-03-07 Impact factor: 56.272
Authors: Kristina D Yakovleva; Diana V Dmitrenko; Iulia S Panina; Anna A Usoltseva; Kirill A Gazenkampf; Olga V Konovalenko; Elena A Kantimirova; Maxim A Novitsky; Regina F Nasyrova; Natalia A Shnayder Journal: Int J Mol Sci Date: 2022-01-16 Impact factor: 5.923